Metenkefalin is an investigational endogenous opioid being studied for the treatment of COVID-19. It has been shown to reduce chromosomal abberations in patients with multiple sclerosis.
- Mechanism
- Curator reviewed · 3 references
Metenkefalin is an agonist of µ and δ opioid receptors. It also causes immunostimulation at low doses and immunosuppression at higher doses. Metenkefalin can also inhibit the production of aldosterone, deoxycorticosterone, and corticosterone. Unfortunately, the mechanisms by which these effects occur have not been well described in the literature.
- Primary indication
- Metenkefalin is indicated in Bosnia for the treatment of relapsing-remitting multiple sclerosis.Curator reviewed
- Formula / weight
- C27H35N5O7S · 573.67 g/mol (avg)
- Also known as
- [met5]-enkephalin · Methionine Enkephalin
- Code names
- INNO-105
Resolves to
YFGBQHOOROIVKG-FKBYEOEOSA-NSMILESCSCC[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(O)=OWhat you can answer from here — as of July 17, 2026
Which drugs share a target with Metenkefalin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account